Developer docs
API playgroundTry for free, no card

Search company profiles

Amplo Biotechnology

Full company profile

uuid0002dwa

Namestring
Amplo Biotechnology
Legal namestring
Amplo Biotechnology
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Amplo Biotechnology is a San Diego-based, privately held clinical-stage gene therapy company founded in 2021 that develops adeno-associated virus (AAV) therapies for diseases of the neuromuscular junction (NMJ). The company's pipeline centers on two candidates: AMP-101, an AAV-Dok7 therapy delivering the Dok-7 protein to treat Dok-7 Congenital Myasthenic Syndrome, and AMP-201, an AAV-Collagen-Q therapy expressing ColQ to treat ColQ Congenital Myasthenic Syndrome. Both candidates are built on Amplo's proprietary ASSET targeting platform, which is designed for muscle-targeted AAV delivery and is being applied initially to rare and ultra-rare patient populations.

Amplo's development strategy emphasizes capital efficiency and risk containment by using established AAV delivery technologies and manufacturing methods rather than novel platforms, concentrating development risk on indication selection. The company states it works with leading global NMJ experts and is dedicated exclusively to AAV therapies for the neuromuscular junction, with stated downstream ambitions into Emery-Dreyfuss Muscular Dystrophy, ALS, and ageing-related neuromuscular conditions. As of the most recent data, the lead candidate is at selection stage with an estimated 10-12 months remaining before clinical trial application.

The company is pre-revenue and does not yet have commercialized products or disclosed pricing. Its capital base consists of a 2021 Series Seed led by BioBrit, LLC with participation from Casdin Capital and SeedFolio (approximately $2.24M disclosed), non-dilutive NIH-NIAMS Fast Track Phase I/II STTR grant funding awarded in 2023, and a $2.89M award from the California Institute for Regenerative Medicine in early 2025. Go-to-market positioning targets rare disease channels, with future commercialization expected through specialty pharmacy and hospital-based distribution typical of rare disease gene therapies.

Short descriptiontext

Amplo Biotechnology is a San Diego-based private biotech developing AAV gene therapies (AMP-101 and AMP-201) targeting rare and ultra-rare neuromuscular junction disorders, including Congenital Myasthenic Syndromes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPompano Beach, United States
HQ citystring
Pompano Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, neuromuscular junction disorders, congenital myasthenic syndromes, muscle-targeted therapy, rare disease therapeutics
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy for Neuromuscular Junction Disorders
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Product Revenue
TypeOne Time License
Description

Pre-revenue biotech company developing gene therapy products for neuromuscular junction disorders. Expected to generate revenue through commercialization of AMP-101 and AMP-201 therapies upon successful clinical development and regulatory approval.

finsmes.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amplo Biotechnology develops muscle-targeted adeno-associated virus (AAV) gene therapies for diseases of the neuromuscular junction (NMJ). Its pipeline includes AMP-101 (AAV-Dok7) for Congenital Myasthenic Syndromes (CMS) and AMP-201 (AAV-Collagen-Q) for ColQ CMS, designed to deliver therapeutic proteins that address the genetic root causes of NMJ dysfunction. The company uses its proprietary ASSET targeting platform combined with established AAV delivery and manufacturing methods to pursue a capital-efficient development path for rare and ultra-rare patient populations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Amplo Biotechnology is a biotech company developing gene therapies for neuromuscular junction disorders. The company operates the ASSET platform for AAV-based gene therapy delivery. Their pipeline consists of two main gene therapy candidates: AMP-101 (AAV-Dok7 therapy targeting Dok-7 congenital myasthenic syndrome) and AMP-201 (AAV-Collagen-Q therapy targeting ColQ congenital myasthenic syndrome). The company uses known delivery technologies and manufacturing methods to reduce development risk while focusing capital efficiency on rare and ultra-rare patient populations.

Product and service2 records
1AMP-101 (AAV-Dok7)
CategoryGene Therapy / AAV Therapy
Description

Muscle-targeted AAV gene therapy delivering the Dok-7 protein for the treatment of Congenital Myasthenic Syndromes (CMS), a group of genetic diseases of the neuromuscular junction. Dok-7 is central to the development and maintenance of the neuromuscular junction. Downstream applications include Emery-Dreyfuss Muscular Dystrophy, ALS, and ageing-related neuromuscular conditions. Intended for patients with Dok-7 CMS and related NMJ disorders.

2AMP-201 (AAV-Collagen-Q)
CategoryGene Therapy / AAV Therapy
Description

AAV gene therapy based on targeted expression of the Collagen Q (ColQ) protein for the treatment of ColQ Congenital Myasthenic Syndrome. ColQ is critical for anchoring acetylcholinesterase at neuromuscular junction endplates and is essential for normal skeletal muscle function. Intended for patients with ColQ CMS caused by collagen Q deficiency.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sarepta is a commercial-stage gene therapy leader for Duchenne muscular dystrophy (Elevidys AAV therapy) and other neuromuscular diseases. Comparable to Amplo because it targets muscle-based genetic diseases with AAV gene therapy, though it operates at vastly greater scale and broader indication set.

TypeBroad incumbent
Description

Regenxbio is an established AAV gene therapy platform company developing therapeutics for rare diseases including neuromuscular conditions. Comparable as it licenses/provides AAV delivery technology and develops its own pipeline, though it serves a much broader therapeutic portfolio than Amplo's NMJ focus.

TypeDirect peer
Description

Solid Biosciences develops AAV gene therapies for Duchenne muscular dystrophy and other neuromuscular genetic diseases. Highly comparable to Amplo's muscle-targeted AAV approach, although at more advanced clinical stage and focused on DMD rather than NMJ biology.

TypeDirect peer
Description

Genethon is a French non-profit developing AAV gene therapies primarily for neuromuscular diseases including spinal muscular atrophy and Duchenne. Directly comparable as a neuromuscular-focused gene therapy developer with similar mission scope to Amplo's NMJ focus.

TypeEmerging player
Description

Taysha is a clinical-stage gene therapy company targeting rare monogenic diseases of the CNS and peripheral nervous system using AAV. Comparable as an early-stage rare disease AAV company, though its CNS focus differs from Amplo's NMJ specialization.

TypeBroad incumbent
Description

Voyager develops AAV gene therapies for neurological diseases including ALS and Huntington's. Comparable for AAV platform approach and neuromuscular disease overlap (ALS), though Voyager is more advanced and broader in CNS scope.

7Astellas Gene Therapies (formerly Audentes)
TypeBroad incumbent
Description

Astellas Gene Therapies develops AAV-based gene therapies including AT132 for X-linked myotubular myopathy, a severe neuromuscular disease. Directly comparable in AAV gene therapy approach and neuromuscular indication overlap, though operating as part of a major pharma.

TypeBroad incumbent
Description

Pfizer acquired Bamboo Therapeutics to build a neuromuscular gene therapy franchise (including DMD and LGMD programs) and continues to invest in this space. Comparable for neuromuscular AAV gene therapy focus, though at much greater scale and broader portfolio.

TypeEmerging player
Description

Kate Therapeutics is an early-stage gene therapy company focused on muscle and CNS diseases using novel AAV capsids. Comparable as a small emerging player developing muscle-targeted AAV therapies for genetic neuromuscular diseases, overlapping with Amplo's indication strategy.

TypeEmerging player
Description

Lexeo Therapeutics develops AAV-based gene therapies for rare cardiac and neurological diseases from Weill Cornell. Comparable as a clinical-stage rare disease gene therapy company with platform-based approach, though focused more on cardiac and CNS indications than NMJ.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amplo Biotechnology

Gene Therapy for Neuromuscular Junction Disordersamplobiotechnology.com

Amplo Biotechnology is a San Diego-based private biotech developing AAV gene therapies (AMP-101 and AMP-201) targeting rare and ultra-rare neuromuscular junction disorders, including Congenital Myasthenic Syndromes.

What Amplo Biotechnology does

Amplo Biotechnology is a San Diego-based, privately held clinical-stage gene therapy company founded in 2021 that develops adeno-associated virus (AAV) therapies for diseases of the neuromuscular junction (NMJ). The company's pipeline centers on two candidates: AMP-101, an AAV-Dok7 therapy delivering the Dok-7 protein to treat Dok-7 Congenital Myasthenic Syndrome, and AMP-201, an AAV-Collagen-Q therapy expressing ColQ to treat ColQ Congenital Myasthenic Syndrome. Both candidates are built on Amplo's proprietary ASSET targeting platform, which is designed for muscle-targeted AAV delivery and is being applied initially to rare and ultra-rare patient populations.

Amplo's development strategy emphasizes capital efficiency and risk containment by using established AAV delivery technologies and manufacturing methods rather than novel platforms, concentrating development risk on indication selection. The company states it works with leading global NMJ experts and is dedicated exclusively to AAV therapies for the neuromuscular junction, with stated downstream ambitions into Emery-Dreyfuss Muscular Dystrophy, ALS, and ageing-related neuromuscular conditions. As of the most recent data, the lead candidate is at selection stage with an estimated 10-12 months remaining before clinical trial application.

The company is pre-revenue and does not yet have commercialized products or disclosed pricing. Its capital base consists of a 2021 Series Seed led by BioBrit, LLC with participation from Casdin Capital and SeedFolio (approximately $2.24M disclosed), non-dilutive NIH-NIAMS Fast Track Phase I/II STTR grant funding awarded in 2023, and a $2.89M award from the California Institute for Regenerative Medicine in early 2025. Go-to-market positioning targets rare disease channels, with future commercialization expected through specialty pharmacy and hospital-based distribution typical of rare disease gene therapies.

Amplo Biotechnology firmographics

Firmographics
Name
Amplo Biotechnology
Legal name
Amplo Biotechnology
Website
https://amplobiotechnology.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Amplo Biotechnology is a San Diego-based private biotech developing AAV gene therapies (AMP-101 and AMP-201) targeting rare and ultra-rare neuromuscular junction disorders, including Congenital Myasthenic Syndromes.
Ownership category
akta.pro rank

Amplo Biotechnology industry classification

Industry
Product category
Gene Therapy for Neuromuscular Junction Disorders
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • AAV gene therapy
  • Neuromuscular junction disorders
  • Congenital myasthenic syndromes
  • Muscle-targeted therapy
  • Rare disease therapeutics

Where Amplo Biotechnology is headquartered

Location

Headquarters

HQ city
Pompano Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Amplo Biotechnology business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Gene Therapy Product Revenue: Pre-revenue biotech company developing gene therapy products for neuromuscular junction disorders. Expected to generate revenue through commercialization of AMP-101 and AMP-201 therapies upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Marketing channels4 records

Amplo Biotechnology product offering

Product offering

Core offering

Amplo Biotechnology develops muscle-targeted adeno-associated virus (AAV) gene therapies for diseases of the neuromuscular junction (NMJ). Its pipeline includes AMP-101 (AAV-Dok7) for Congenital Myasthenic Syndromes (CMS) and AMP-201 (AAV-Collagen-Q) for ColQ CMS, designed to deliver therapeutic proteins that address the genetic root causes of NMJ dysfunction. The company uses its proprietary ASSET targeting platform combined with established AAV delivery and manufacturing methods to pursue a capital-efficient development path for rare and ultra-rare patient populations.

Product overview

Amplo Biotechnology is a biotech company developing gene therapies for neuromuscular junction disorders. The company operates the ASSET platform for AAV-based gene therapy delivery. Their pipeline consists of two main gene therapy candidates: AMP-101 (AAV-Dok7 therapy targeting Dok-7 congenital myasthenic syndrome) and AMP-201 (AAV-Collagen-Q therapy targeting ColQ congenital myasthenic syndrome). The company uses known delivery technologies and manufacturing methods to reduce development risk while focusing capital efficiency on rare and ultra-rare patient populations.

Differentiator

Problem solved

Functional benefit

Products and services

  • AMP-101 (AAV-Dok7) Muscle-targeted AAV gene therapy delivering the Dok-7 protein for the treatment of Congenital Myasthenic Syndromes (CMS), a group of genetic diseases of the neuromuscular junction. Dok-7 is central to the development and maintenance of the neuromuscular junction. Downstream applications include Emery-Dreyfuss Muscular Dystrophy, ALS, and ageing-related neuromuscular conditions. Intended for patients with Dok-7 CMS and related NMJ disorders.
  • AMP-201 (AAV-Collagen-Q) AAV gene therapy based on targeted expression of the Collagen Q (ColQ) protein for the treatment of ColQ Congenital Myasthenic Syndrome. ColQ is critical for anchoring acetylcholinesterase at neuromuscular junction endplates and is essential for normal skeletal muscle function. Intended for patients with ColQ CMS caused by collagen Q deficiency.

Companies that use Amplo Biotechnology

Customer profile

Segments1 record

Ideal customer profiles1 record

Amplo Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Amplo Biotechnology partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Amplo Biotechnology competitors and assessment

Company assessment

Broad incumbents

  • Sarepta Therapeutics: Sarepta is a commercial-stage gene therapy leader for Duchenne muscular dystrophy (Elevidys AAV therapy) and other neuromuscular diseases. Comparable to Amplo because it targets muscle-based genetic diseases with AAV gene therapy, though it operates at vastly greater scale and broader indication set.
  • Regenxbio: Regenxbio is an established AAV gene therapy platform company developing therapeutics for rare diseases including neuromuscular conditions. Comparable as it licenses/provides AAV delivery technology and develops its own pipeline, though it serves a much broader therapeutic portfolio than Amplo's NMJ focus.
  • Voyager Therapeutics: Voyager develops AAV gene therapies for neurological diseases including ALS and Huntington's. Comparable for AAV platform approach and neuromuscular disease overlap (ALS), though Voyager is more advanced and broader in CNS scope.
  • Astellas Gene Therapies (formerly Audentes): Astellas Gene Therapies develops AAV-based gene therapies including AT132 for X-linked myotubular myopathy, a severe neuromuscular disease. Directly comparable in AAV gene therapy approach and neuromuscular indication overlap, though operating as part of a major pharma.
  • Pfizer (Bamboo Therapeutics / Gene Therapy Unit): Pfizer acquired Bamboo Therapeutics to build a neuromuscular gene therapy franchise (including DMD and LGMD programs) and continues to invest in this space. Comparable for neuromuscular AAV gene therapy focus, though at much greater scale and broader portfolio.

Direct peers

  • Solid Biosciences: Solid Biosciences develops AAV gene therapies for Duchenne muscular dystrophy and other neuromuscular genetic diseases. Highly comparable to Amplo's muscle-targeted AAV approach, although at more advanced clinical stage and focused on DMD rather than NMJ biology.
  • Genethon: Genethon is a French non-profit developing AAV gene therapies primarily for neuromuscular diseases including spinal muscular atrophy and Duchenne. Directly comparable as a neuromuscular-focused gene therapy developer with similar mission scope to Amplo's NMJ focus.

Emerging players

  • Taysha Gene Therapies: Taysha is a clinical-stage gene therapy company targeting rare monogenic diseases of the CNS and peripheral nervous system using AAV. Comparable as an early-stage rare disease AAV company, though its CNS focus differs from Amplo's NMJ specialization.
  • Kate Therapeutics: Kate Therapeutics is an early-stage gene therapy company focused on muscle and CNS diseases using novel AAV capsids. Comparable as a small emerging player developing muscle-targeted AAV therapies for genetic neuromuscular diseases, overlapping with Amplo's indication strategy.
  • Lexeo Therapeutics: Lexeo Therapeutics develops AAV-based gene therapies for rare cardiac and neurological diseases from Weill Cornell. Comparable as a clinical-stage rare disease gene therapy company with platform-based approach, though focused more on cardiac and CNS indications than NMJ.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Amplo Biotechnology social profiles

Digital presence

Amplo Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amplo Biotechnology leadership team

Management profile

Number of profiles

Profiles4 records

Amplo Biotechnology funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amplo Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amplo Biotechnology

What does Amplo Biotechnology do?

Amplo Biotechnology develops muscle-targeted adeno-associated virus (AAV) gene therapies for diseases of the neuromuscular junction (NMJ). Its pipeline includes AMP-101 (AAV-Dok7) for Congenital Myasthenic Syndromes (CMS) and AMP-201 (AAV-Collagen-Q) for ColQ CMS, designed to deliver therapeutic proteins that address the genetic root causes of NMJ dysfunction. The company uses its proprietary ASSET targeting platform combined with established AAV delivery and manufacturing methods to pursue a capital-efficient development path for rare and ultra-rare patient populations.

Is Amplo Biotechnology a public or private company?

Amplo Biotechnology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amplo Biotechnology founded?

Amplo Biotechnology was founded in 2021. It employs 1 to 10 people.

Where is Amplo Biotechnology based?

Amplo Biotechnology is headquartered in Pompano Beach, United States, in the North America region.

How does Amplo Biotechnology make money?

One revenue line is on record: gene Therapy Product Revenue.

Who are Amplo Biotechnology's main competitors?

Broad incumbents on record are Sarepta Therapeutics, Regenxbio, Voyager Therapeutics, Astellas Gene Therapies (formerly Audentes) and Pfizer (Bamboo Therapeutics / Gene Therapy Unit). Direct peers are Solid Biosciences and Genethon. Emerging players are Taysha Gene Therapies, Kate Therapeutics and Lexeo Therapeutics.

Does Amplo Biotechnology have an API?

No public API is recorded for Amplo Biotechnology.

What industry is Amplo Biotechnology in?

Amplo Biotechnology's product category is Gene Therapy for Neuromuscular Junction Disorders. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAndelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular JunctionAndelyn Biosciences and Amplo Biotechnology partnered to manufacture clinical-grade AAV material for neuromuscular junction diseases using Andelyn's Curator platform. The collaboration aims to advance Amplo's gene therapy programs toward clinical evaluation, with its lead program AMP-101 targeting Dok7 congenital myasthenic syndrome.FinSMEsAmplo Biotechnology Receives Fast Track Phase I/II STTR Grant from NIH-NIAMSAmplo Biotechnology has received a Fast Track Phase I/II STTR grant from the NIH-NIAMS to advance its AMP-201 gene therapy for congenital myasthenic syndrome. The company will collaborate with UC-Davis researcher Ricardo Maselli, building on data licensed from Nagoya University. This development supports Amplo's broader pipeline, which includes the preclinical AMP-101 program expected to enter clinical trials in 2024.PR NewswireAmplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q DeficiencyAmplo Biotechnology has secured a Fast Track Phase I/II STTR grant from the NIH-NINDS to advance AMP-201, an AAV-based gene therapy targeting Collagen Q deficiency. The company will collaborate with UC-Davis on this project, building upon its existing pipeline which includes AMP-101 expected to enter clinical trials in 2024.PR NewswireAmplo Biotechnology Closes Series Seed Financing to Advance Gene Therapies for The Treatment of Neuromuscular Junction DisordersAmplo Biotechnology announced the closing of a Series Seed financing round led by BioBrit, LLC, with participation from Casdin Capital and SeedFolio. The company was also awarded an NIH Fast-Track Phase I/II SBIR grant for its AMP-101 gene therapy candidate. These funds will support large-scale manufacturing and IND-enabling studies for AMP-101, which targets Dok-7 congenital myasthenic syndrome.BioSpaceAmplo Biotechnology Closes Series Seed Financing to Advance Gene Therapies for The Treatment of Neuromuscular Junction DisordersAmplo Biotechnology closed a Series Seed financing round led by BioBrit, LLC., with participation from Casdin Capital and SeedFolio, to advance its gene therapy candidate AMP-101. The company was also awarded an NIH Fast-Track Phase I/II SBIR grant for the development of this therapy targeting neuromuscular junction disorders. Amplo plans to begin clinical trials for Dok-7 congenital myasthenic syndrome in 2023.SecSEC FORM DThe Securities and Exchange Commission received a Form D from Amplo Biotechnology, Inc., indicating a notice of exempt offering of securities. The total offering amount is reported to be $2,486,712, with $2,235,701 already sold to investors, totaling 15 investors involved in the offering. This offering is not connected to a business combination transaction and is expected to last less than one year.